Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | PPARD | Q03181 | 8/20 | 0.49 |
| ▸ | PPARA | Q07869 | 7/20 | 0.49 |
| ▸ | PPARG | P37231 | 4/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.43 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23512372 | 0.88 | KMT2A (0.51) | KMT2APPARDPPARAPPARGTP53 | |
| SCHEMBL14457826 | 0.88 | KMT2A (0.57) | KMT2APPARDPPARAPPARGAKR1C3 | |
| SCHEMBL23612457 | 0.85 | KMO (0.54) | PPARDPPARAPPARGTP53MAPT | |
| SCHEMBL9191040 | 0.84 | KMT2A (0.57) | KMT2APPARDPPARAPPARGPLA2G4A | |
| SCHEMBL14594510 | 0.84 | ATM (0.55) | TP53MAPTPLA2G4A | |
| SCHEMBL5537950 | 0.81 | KMT2A (0.60) | KMT2APPARDPPARAPPARGMAPT | |
| SCHEMBL12257510 | 0.80 | RORC (0.45) | KMT2AMAPT | |
| SCHEMBL27602809 | 0.79 | KDM4E (0.53) | KMT2APPARDPPARAPPARGMAPT | |
| SCHEMBL4234811 | 0.79 | KMT2A (0.62) | KMT2APPARDPPARAPPARGNTSR1 | |
| SCHEMBL30103437 | 0.79 | KMT2A (0.62) | KMT2APPARDPPARAPPARGNTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230518-A1 | OXADIAZOLE FUSED HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF MULTIPLE SCLEROSIS | MERCK SERONO S.A. (CH) | 2011-09-22 | — | — | US | disclosed |
| US-20070191371-A1 | HETEROCYCLIC MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAP4K2, MAPKAPK5 | KMT2A 1679/4885PPARD 2160/4885PPARA 1610/4885 |
| US-20070191371-A1 | HETEROCYCLIC MODULATORS OF PPAR | PPARG, PPARD, PPARA | KMT2A 3767/4885PPARD 2/4885PPARA 3/4885 |
| US-20110230518-A1 | OXADIAZOLE FUSED HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF MULTIPLE SCLEROSIS | PMP22, AQP4, NDUFS3 | KMT2A 2776/4885PPARD 798/4885PPARA 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.